What we do
The remit of the Scottish Medicines Consortium (SMC) is to provide advice to NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) across Scotland about the clinical and cost-effectiveness of all newly licensed medicines, all new formulations of existing medicines and new indications for established products (licensed from January 2002). Read more on what we do.
Submission Process
Guidelines for Industry
In this section you will find Guidelines for the Pharmaceutical Industry on our submission process.
Guidelines for Patient Involvement Groups
In this section you will find Guidelines for Patient Interest Groups on our submission process.
Find out more
The SMC is a consortium of NHSScotland’s 14 Health Boards. It was established in 2001 to benefit patients by providing NHSScotland with a single source of advice about the value of each new medicine and the patients for whom it would be of most benefit.
Its advice also helps to facilitate the early introduction of beneficial treatments across Scotland.
SMC Advice
Latest Advice
- abiraterone (Zytiga)
- crizotinib (Xalkori)
- lisdexamfetamine dimesylate (Elvanse)
- mirabegron (Betmiga)
- ranibizumab (Lucentis)
- rifampicin, isoniazid, pyrazinamide, ethambutol hydrochloride (Voractiv)
- tafamidis meglumine (Vyndaqel)
- vildagliptin (Galvus)
- vildagliptin / metformin hydrochloride (Eucreas®)
Briefing Note
A monthly Briefing Note is produced to provide a summary of SMC advice. It is written to help members of the media and other interested groups understand the work and advice of the Scottish Medicines Consortium.
Forthcoming Submissions
The Scottish Medicines Consortium meets monthly on the first Tuesday of each month. Click here to view forthcoming submissions that have been scheduled for assessment over the coming 2/3 months.